Navigation Links
Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
Date:8/12/2008

ST. LOUIS, Aug. 12 /PRNewswire-FirstCall/ -- At the Board of Directors meeting held today, the Directors declared a quarterly cash dividend of $.13 per share. The dividend is payable on September 15, 2008 to shareholders of record on September 2, 2008.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. We are committed to accelerating our Customers' success through leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning web site at http://www.sigma-aldrich.com


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Reports 16.7% Gain in Q2 2008 Diluted EPS. Q2 2008 Sales Rise 14.4%. 2008 Diluted EPS Forecast Raised $.05 to $2.62-$2.72.
2. Sigma-Aldrich Corporations 2nd Quarter 2008 Earnings Conference Call
3. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Sigma-Aldrich Announces Collaboration to Develop Monoclonal Antibodies
6. Sigma-Aldrich Signs Agreement With Plextronics to Distribute Plexcore(R) Organic Electronics Materials
7. Sigma-Aldrich to Present at the Nasdaq 21st Investor Program on Wednesday, May 21, 2008
8. Sigma-Aldrich (Nasdaq: SIAL) CAO & CFO Hogan Plans to Retire; Search for Successor Underway
9. Sigma-Aldrich Recognized by BioInformatics, LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs
10. Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries
11. Sigma-Aldrich to Present at the Baird 2008 Growth Stock Conference on Tuesday, May 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... ET; 8:00 a.m. PT, VANCOUVER and SAN DIEGO, ... a clinical-stage developer of drugs for infectious,diseases, will host ... at 11:00 a.m. ET (8:00 a.m. PT) to discuss ... 2008 and provide an update on,company activities. To participate ...
... on Detroit Area, DETROIT, March 11 ... its new study, Affordable Broadband:,Empowering Communities Across the ... to education, health care and civic,involvement in minority ... Empowerment Council (DEC) that was launched,earlier this year ...
... March 11 Haemonetics,Corporation announced today the appointment ... Chief Marketing Officer. In this position, Mr. Allen,will ... portfolio in addition to his current responsibilities as ... commented, "Pete Allen was an,architect of our strategic ...
Cached Biology Technology:Study Finds Broadband Access Key to Empowerment of Minority Communities 2Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer 2
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased ... boosted investments in new testing and inspection technologies. ... given rise to a range of innovative test ... requirements of Generation Y, which is generally more ... a result, product development strategies of test equipment ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... ., a full-service contract research organization (CRO), will host ... CRO statisticians," at the Joint Statistical Meetings (JSM) ... The roundtable will be moderated by Jia Hu, biostatistician ... statisticians held in North America, attended by more than ...
... New research published in the Journal of the ... raisins may provide the same workout boost as sports ... of California-Davis, the study evaluated the effects that natural ... Runners depleted their glycogen stores in an 80-minute ...
... led by scientists at USC was the first to identify ... is another twist to what limits life in the ocean," ... the USC Dornsife College of Letters, Arts and Sciences and ... will appear in Proceedings of the National Academy of ...
Cached Biology News:Synteract to Host Joint Statistical Meeting Roundtable in San Diego 2Synteract to Host Joint Statistical Meeting Roundtable in San Diego 3Scientists confirm existence of vitamin 'deserts' in the ocean 2
Human FADD Affinity Purified Polyclonal Ab...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: